• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:07:47 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    8-K
    0001681087false00016810872025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    Tectonic Therapeutic, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38537

    81-0710585

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    490 Arsenal Way

    Suite 210

     

    Watertown, Massachusetts

     

    02472

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (339) 666-3320

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    TECX

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    99.1

    Press Release of Tectonic Therapeutic, Inc. dated May 8, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Tectonic Therapeutic, Inc.

     

     

     

     

    Date:

    May 8, 2025

    By:

    /s/ Daniel Lochner

     

     

     

    Daniel Lochner
    Chief Financial Officer

     


    Get the next $TECX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

      SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      11/14/24 4:05:11 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/28/24 6:08:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

      SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      10/24/24 5:12:09 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

      Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat

      5/17/25 10:40:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

      Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including

      5/8/25 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The

      5/7/25 8:00:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Financials

    Live finance-specific insights

    See more
    • Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

      TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

      1/30/25 6:30:00 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

      Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

      11/7/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

      TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

      8/14/24 4:01:00 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      2/7/25 4:21:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/11/25 6:12:08 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/9/25 5:38:10 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mcguire Terrance sold $8,550,000 worth of shares (500,000 units at $17.10) (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      4/7/25 5:02:43 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/15/25 2:24:51 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

      SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      5/12/25 10:43:30 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Tectonic Therapeutic Inc.

      424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      5/8/25 4:33:19 PM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tectonic Therapeutic with a new price target

      Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

      4/21/25 8:39:06 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Tectonic Therapeutic with a new price target

      Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

      11/20/24 7:46:41 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

      Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

      8/22/24 7:34:40 AM ET
      $TECX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care